Syndrome News and Research

RSS

Reinfection with SARS-CoV-2 in children

These findings bear out earlier reports that COVID-19 is less frequent and severe in children than adults.

7 Jan 2022

SARS-CoV-2 Omicron variant leads to widespread escape from neutralizing antibody responses

A new study reported the neutralization of Omicron by a large panel of sera collected from convalescent early pandemic, Alpha, Beta, Gamma and Delta infected individuals, as well as among vaccinees receiving three doses of the Oxford/AstraZeneca (AZD1222) or the Pfizer BioNtech (BNT16b2) vaccines.

7 Jan 2022

Model suggests feasibility of shorter COVID-19 isolation period with minimal risk

Researchers set up a model that included parameters such as the infectiousness of the individual, and lateral flow testing, in order to assess the effectiveness of test-to-release policies as compared to those with fixed-duration isolation mandates

7 Jan 2022

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

A new study assessed the levels of infectious virus (obtained from the nasopharynx) in vaccinated and unvaccinated individuals.

7 Jan 2022

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Researchers from India have now successfully grown and isolated the Omicron variant from hamsters in vivo with further culturing in the Vero CCL-81 cells in vitro, in a step forward towards testing the effectiveness of existing SARS-CoV-2 vaccines and generation of new Omicron appropriate vaccines.

7 Jan 2022

Epidemic model for estimating relative transmissibility and immune escape of SARS-CoV-2 Omicron variant in South Africa

A new study developed a stochastic, multi-strain, compartmental epidemic model to estimate the relative transmissibility and immune escape capacity of the Omicron variant.

7 Jan 2022

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron.

7 Jan 2022

Additional SARS-CoV-2 vaccine doses elicit robust seroresponse among patients receiving maintenance dialysis

Researchers thus recently published a report wherein they examined the seroresponse to an additional dose of vaccine in patients on maintenance dialysis.

7 Jan 2022

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Researchers from various institutions describe the characteristics, costs, and healthcare resource use associated with pediatric COVID-19 patients.

7 Jan 2022

Association of obstructive sleep apnea with hospitalization due to COVID-19

Researchers report that OSA is an independent risk factor for severe COVID-19.

7 Jan 2022

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

SARS-CoV-2 Omicron less pathogenic in hamsters

A new research paper posted as a preprint to the bioRxiv* server attempts to throw some light on this question by studying viral pathogenicity in golden hamsters, a valuable model for severe COVID-19 due to the development of reproducible weight loss and pneumonia after infection with the virus.

6 Jan 2022

Syndrome News and Research

Reinfection with SARS-CoV-2 in children

SARS-CoV-2 Omicron variant leads to widespread escape from neutralizing antibody responses

Model suggests feasibility of shorter COVID-19 isolation period with minimal risk

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Epidemic model for estimating relative transmissibility and immune escape of SARS-CoV-2 Omicron variant in South Africa

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

Additional SARS-CoV-2 vaccine doses elicit robust seroresponse among patients receiving maintenance dialysis

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Association of obstructive sleep apnea with hospitalization due to COVID-19

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

SARS-CoV-2 Omicron less pathogenic in hamsters

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

How effective are COVID-19 vaccines against the Omicron and Delta variants?

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Scientists assess effectiveness of neutralizing antibodies against seven SARS-CoV-2 variants, including Omicron

Antibody binding response significantly reduced for Omicron compared to other SARS-CoV-2 variants

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News